Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the fourteen brokerages that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $14.85.

Several equities research analysts have recently weighed in on the company. Piper Sandler raised their price objective on Hims & Hers Health from $9.00 to $11.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 27th. Jefferies Financial Group reiterated a "hold" rating and issued a $15.00 price target (down previously from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. TheStreet raised Hims & Hers Health from a "d" rating to a "c" rating in a research note on Monday, March 4th. SVB Leerink began coverage on shares of Hims & Hers Health in a research note on Monday, February 26th. They set a "market perform" rating and a $10.00 price objective for the company. Finally, Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They issued a "buy" rating and a $20.00 target price for the company.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded down $0.98 during trading on Friday, hitting $11.26. The stock had a trading volume of 12,039,588 shares, compared to its average volume of 4,102,149. The business has a fifty day moving average of $14.01 and a two-hundred day moving average of $10.31. Hims & Hers Health has a fifty-two week low of $5.65 and a fifty-two week high of $17.16. The firm has a market cap of $2.41 billion, a P/E ratio of -102.36 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.02) by $0.03. The business had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business's revenue for the quarter was up 47.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.05) EPS. As a group, research analysts forecast that Hims & Hers Health will post 0.11 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of the business's stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $40,922.40. Following the completion of the sale, the insider now directly owns 154,345 shares of the company's stock, valued at $1,548,080.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the company's stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 4,080 shares of the firm's stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $40,922.40. Following the completion of the transaction, the insider now directly owns 154,345 shares in the company, valued at $1,548,080.35. The disclosure for this sale can be found here. Insiders sold 736,191 shares of company stock valued at $9,733,700 in the last three months. Corporate insiders own 31.63% of the company's stock.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter worth $48,000. Belpointe Asset Management LLC acquired a new position in Hims & Hers Health during the 3rd quarter worth $76,000. EMC Capital Management boosted its holdings in Hims & Hers Health by 80.0% during the third quarter. EMC Capital Management now owns 12,000 shares of the company's stock valued at $79,000 after acquiring an additional 5,332 shares during the period. Certuity LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $109,000. Finally, Corton Capital Inc. acquired a new stake in shares of Hims & Hers Health in the third quarter valued at about $122,000. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.